journal article·2023-07Open access

Targeting L‐Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment

Yipeng Zhao, Jie Zhang, Xi Cheng, Wenping Huang, Shishi Shen, Shilin Wu, Yiying Huang, Guangjun Nie, Hai Wang, Wei Qiu

Advanced Science· Volume 10· Issue 20

Abstract

Abstract Inflammation induced by autoreactive CD4+ T lymphocytes is a major factor in the pathogenesis of multiple sclerosis (MS). Immunosuppressive drugs, such as FTY720, are subsequently developed to prevent the migration of CD4+ T lymphocytes to the central nervous system (CNS). However, these immunosuppressive drugs have limited accumulation in lymph nodes (LNs), resulting in poor efficacy. Here, this work develops a nanoplatform for delivering immunosuppressive drugs to LNs for durable MS treatment. Human CD47 peptide and L‐selectin targeting aptamer are modified on the nanoparticles encapsulated with FTY720 (clnFTY) for self‐passivation and the targeting of L‐selectin on lymphocytes, a homing receptor for T‐cells entering LNs. Using this natural process, clnFTY nanoparticles efficiently deliver FTY720 to LNs and delay disease progression in experimental autoimmune encephalomyelitis (EAE) mice following a single dose treatment over a 42‐day observational period. Considering the daily dosing requirement of FTY720, this strategy greatly improves its therapeutic efficiency. The ability of clnFTY nanoparticles to target lymphocytes, reduce sphingosine‐1‐phosphate receptor 1 (S1PR1) expression, and suppress inflammatory cytokines release are demonstrated in clinical blood samples from MS patients. Taken together, this study demonstrates that targeted LNs delivery may greatly extend the treatment cycle of immunosuppressive drugs for durable MS treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Sphingolipid Metabolism and Signaling · Immunotherapy and Immune Responses · T-cell and B-cell Immunology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurology The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou 510000 China

CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology Beijing 100190 China

School of Nanoscience and Engineering University of Chinese Academy of Sciences 100049 Beijing China

Funding

Natural Science Foundation of Guangdong Province · National Natural Science Foundation of China

References (45)

Show source-provided references
1. 10.1038/s41577-022-00718-z10.1038/s41577-022-00718-z ↗
2. 10.1038/nrneurol.2014.3710.1038/nrneurol.2014.37 ↗
3. 10.1038/s41467-020-15543-y10.1038/s41467-020-15543-y ↗
4. 10.1016/j.autrev.2020.10264710.1016/j.autrev.2020.102647 ↗
5. 10.1016/j.bbi.2010.01.01410.1016/j.bbi.2010.01.014 ↗
6. 10.1212/WNL.49.2.35110.1212/WNL.49.2.351 ↗
7. 10.1038/s41467-020-17629-z10.1038/s41467-020-17629-z ↗
8. 10.1038/s41593-021-00801-z10.1038/s41593-021-00801-z ↗
9. 10.1001/jamaneurol.2016.082610.1001/jamaneurol.2016.0826 ↗
10. 10.1038/nrd324810.1038/nrd3248 ↗
11. 10.1016/S0140-6736(21)00244-010.1016/S0140-6736(21)00244-0 ↗
12. 10.1007/s40265-016-0603-210.1007/s40265-016-0603-2 ↗
13. 10.1212/01.wnl.0000338569.32367.3d10.1212/01.wnl.0000338569.32367.3d ↗
14. 10.1038/nrd409910.1038/nrd4099 ↗
15. 10.1016/j.repc.2014.11.01210.1016/j.repc.2014.11.012 ↗
16. 10.1016/j.msard.2012.11.00410.1016/j.msard.2012.11.004 ↗
17. 10.1111/ene.1369410.1111/ene.13694 ↗
18. 10.1016/j.bbi.2015.06.01910.1016/j.bbi.2015.06.019 ↗
19. 10.1002/adma.20220595010.1002/adma.202205950 ↗
20. 10.1002/adma.20220722710.1002/adma.202207227 ↗
21. 10.1126/sciadv.aaz446210.1126/sciadv.aaz4462 ↗
22. 10.1038/4438510.1038/44385 ↗
23. 10.1084/jem.180.6.240110.1084/jem.180.6.2401 ↗
24. 10.1182/blood-2006-04-01979410.1182/blood-2006-04-019794 ↗
25. 10.1038/nature1893510.1038/nature18935 ↗
26. 10.1038/s41577-021-00539-610.1038/s41577-021-00539-6 ↗
27. 10.4049/jimmunol.164.10.547410.4049/jimmunol.164.10.5474 ↗
28. 10.1084/jem.2012050210.1084/jem.20120502 ↗
29. 10.1007/s40265-021-01528-810.1007/s40265-021-01528-8 ↗
30. 10.4049/jimmunol.176.9.565210.4049/jimmunol.176.9.5652 ↗
31. 10.1038/sj.bjp.070518210.1038/sj.bjp.0705182 ↗
32. 10.1007/s00401-016-1631-410.1007/s00401-016-1631-4 ↗
33. 10.1016/S1474-4422(14)70049-310.1016/S1474-4422(14)70049-3 ↗
34. 10.1186/s12974-018-1208-310.1186/s12974-018-1208-3 ↗
35. 10.1146/annurev.immunol.23.021704.11570710.1146/annurev.immunol.23.021704.115707 ↗
36. 10.1002/eji.20063632210.1002/eji.200636322 ↗
37. 10.1002/advs.20210204310.1002/advs.202102043 ↗
38. 10.1016/j.immuni.2020.07.00810.1016/j.immuni.2020.07.008 ↗
39. 10.1016/S1474-4422(17)30408-810.1016/S1474-4422(17)30408-8 ↗
40. 10.1016/S1474-4422(08)70092-910.1016/S1474-4422(08)70092-9 ↗
41. 10.1111/cns.1377910.1111/cns.13779 ↗
42. 10.1172/jci.insight.14520710.1172/jci.insight.145207 ↗
43. 10.1038/nm.380410.1038/nm.3804 ↗
44. 10.1002/eji.20194841010.1002/eji.201948410 ↗
45. 10.1177/135245851139888510.1177/1352458511398885 ↗